Using computer methods to design drugs that target proteins involved in cancer.
Computer-Aided Drug Design Targeting Protein Phosphorylation
This study is looking at new ways to create drugs that can better target proteins involved in lung cancer, especially for patients with certain mutations, by using computer simulations to see how these drugs work, which could lead to more effective treatments for you.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-St. Louis NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11123561 on NIH RePORTER |
What this research studies
This research focuses on developing advanced computational techniques to design drugs that specifically target protein kinases, which are crucial in cancer treatment. By simulating how these drugs interact with proteins, the researchers aim to identify compounds that can effectively bind to and inhibit cancer-related proteins, particularly in lung cancer patients with specific mutations. The study will utilize molecular simulations and machine learning to enhance the prediction of drug responses, potentially leading to more effective therapies for patients. The research also aims to improve the understanding of how different mutations in proteins affect drug binding and efficacy.
Who could benefit from this research
Good fit: Ideal candidates for this research are lung cancer patients with specific mutations in the epidermal growth factor receptor (EGFR).
Not a fit: Patients without lung cancer or those whose cancer is not driven by mutations in EGFR may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective cancer treatments tailored to the genetic profiles of patients.
How similar studies have performed: Previous research has successfully developed protein kinase inhibitors, indicating that this approach has potential for further advancements in cancer treatment.
Where this research is happening
Saint Louis, United States
- University of Missouri-St. Louis — Saint Louis, United States (Active)
Researchers
- Principal investigator: Wong, Chung F. — University of Missouri-St. Louis
- Study coordinator: Wong, Chung F.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.